Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07293897) titled 'A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)' on Dec. 17, 2025.
Study Type: Observational
Primary Sponsor: Takeda
Condition:
Alagille Syndrome (ALGS)
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention:
Drug: Maralixibat
Recruitment Status: Not recruiting
Date of First Enrollment: January 9, 2026
Target Sample Size: 50
To know more, visit https://clinicaltrials.gov/study/NCT07293897
Published by HT Digital Content Services with permission from Health Daily Digest....